At SABCS 2024, Dr. Janice Tsang explored key developments in early breast cancer (EBC) treatment, highlighting the transition from conventional approaches to more personalized, biomarker-driven strategies. The discussion addressed de-escalation of radiotherapy, long-term updates on adjuvant therapies, and the expanding role of immunotherapy (IO) in triple-negative breast cancer (TNBC) and high-risk HR+/HER2- disease.
Key questions were raised about the necessity of anthracyclines and chemotherapy in certain subgroups, the potential of adaptive IO strategies, and the growing importance of biological markers like TILs and ctDNA in treatment decision-making. With new data from KEYNOTE-522, NATALEE, and OlympiA, the field is evolving toward a more tailored, patient-specific approach to optimize outcomes while minimizing toxicity.
For more insights, visit SABCS 2024.
